Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 2000 May-Jun;6(3):228–237. doi: 10.3201/eid0603.000302

A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States.

M F Rupnow 1, R D Shachter 1, D K Owens 1, J Parsonnet 1
PMCID: PMC2640864  PMID: 10827112

Abstract

To assess the benefits of intervention programs against Helicobacter pylori infection, we estimated the baseline curves of its incidence and prevalence. We developed a mathematical (compartmental) model of the intrinsic dynamics of H. pylori, which represents the natural history of infection and disease progression. Our model divided the population according to age, infection status, and clinical state. Case-patients were followed from birth to death. A proportion of the population acquired H. pylori infection and became ill with gastritis, duodenal ulcer, chronic atrophic gastritis, or gastric cancer. We simulated the change in transmissibility consistent with the incidence of gastric cancer and duodenal ulcer over time, as well as current H. pylori prevalence. In the United States, transmissibility of H. pylori has decreased to values so low that, should this trend continue, the organism will disappear from the population without targeted intervention; this process, however, will take more than a century.

Full Text

The Full Text of this article is available as a PDF (211.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banatvala N., Mayo K., Megraud F., Jennings R., Deeks J. J., Feldman R. A. The cohort effect and Helicobacter pylori. J Infect Dis. 1993 Jul;168(1):219–221. doi: 10.1093/infdis/168.1.219. [DOI] [PubMed] [Google Scholar]
  2. Blaser M. J., Chyou P. H., Nomura A. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res. 1995 Feb 1;55(3):562–565. [PubMed] [Google Scholar]
  3. Bonnevie O. The incidence of duodenal ulcer in Copenhagen county. Scand J Gastroenterol. 1975;10(4):385–393. [PubMed] [Google Scholar]
  4. Bonnevie O. The incidence of gastric ulcer in Copenhagen county. Scand J Gastroenterol. 1975;10(3):231–239. [PubMed] [Google Scholar]
  5. Correa P., Cuello C., Duque E., Burbano L. C., Garcia F. T., Bolanos O., Brown C., Haenszel W. Gastric cancer in Colombia. III. Natural history of precursor lesions. J Natl Cancer Inst. 1976 Nov;57(5):1027–1035. doi: 10.1093/jnci/57.5.1027. [DOI] [PubMed] [Google Scholar]
  6. Feldman R. A., Eccersley A. J., Hardie J. M. Epidemiology of Helicobacter pylori: acquisition, transmission, population prevalence and disease-to-infection ratio. Br Med Bull. 1998;54(1):39–53. doi: 10.1093/oxfordjournals.bmb.a011678. [DOI] [PubMed] [Google Scholar]
  7. Graham D. Y. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology. 1997 Dec;113(6):1983–1991. doi: 10.1016/s0016-5085(97)70019-2. [DOI] [PubMed] [Google Scholar]
  8. Graham D. Y. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol. 1991 Mar-Apr;6(2):105–113. doi: 10.1111/j.1440-1746.1991.tb01448.x. [DOI] [PubMed] [Google Scholar]
  9. Hansson L. E., Nyrén O., Hsing A. W., Bergström R., Josefsson S., Chow W. H., Fraumeni J. F., Jr, Adami H. O. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med. 1996 Jul 25;335(4):242–249. doi: 10.1056/NEJM199607253350404. [DOI] [PubMed] [Google Scholar]
  10. Karnes W. E., Jr, Samloff I. M., Siurala M., Kekki M., Sipponen P., Kim S. W., Walsh J. H. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology. 1991 Jul;101(1):167–174. doi: 10.1016/0016-5085(91)90474-y. [DOI] [PubMed] [Google Scholar]
  11. Kuipers E. J. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther. 1997 Apr;11 (Suppl 1):71–88. doi: 10.1046/j.1365-2036.11.s1.5.x. [DOI] [PubMed] [Google Scholar]
  12. Kuipers E. J., Thijs J. C., Festen H. P. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther. 1995;9 (Suppl 2):59–69. [PubMed] [Google Scholar]
  13. Kurata J. H., Honda G. D., Frankl H. The incidence of duodenal and gastric ulcers in a large health maintenance organization. Am J Public Health. 1985 Jun;75(6):625–629. doi: 10.2105/ajph.75.6.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Olshansky S. J., Carnes B. A. Ever since Gompertz. Demography. 1997 Feb;34(1):1–15. [PubMed] [Google Scholar]
  15. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9 (Suppl 2):45–51. [PubMed] [Google Scholar]
  16. Porco T. C., Blower S. M. Quantifying the intrinsic transmission dynamics of tuberculosis. Theor Popul Biol. 1998 Oct;54(2):117–132. doi: 10.1006/tpbi.1998.1366. [DOI] [PubMed] [Google Scholar]
  17. Schultze V., Hackelsberger A., Günther T., Miehlke S., Roessner A., Malfertheiner P. Differing patterns of Helicobacter pylori gastritis in patients with duodenal, prepyloric, and gastric ulcer disease. Scand J Gastroenterol. 1998 Feb;33(2):137–142. doi: 10.1080/00365529850166851. [DOI] [PubMed] [Google Scholar]
  18. Sipponen P. Helicobacter pylori gastritis--epidemiology. J Gastroenterol. 1997 Apr;32(2):273–277. doi: 10.1007/BF02936382. [DOI] [PubMed] [Google Scholar]
  19. Sipponen P., Kekki M., Haapakoski J., Ihamäki T., Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer. 1985 Feb 15;35(2):173–177. doi: 10.1002/ijc.2910350206. [DOI] [PubMed] [Google Scholar]
  20. Sonnenberg A. Factors which influence the incidence and course of peptic ulcer. Scand J Gastroenterol Suppl. 1988;155:119–140. doi: 10.3109/00365528809096294. [DOI] [PubMed] [Google Scholar]
  21. Sonnenberg A. Geographic and temporal variations in the occurrence of peptic ulcer disease. Scand J Gastroenterol Suppl. 1985;110:11–24. doi: 10.3109/00365528509095826. [DOI] [PubMed] [Google Scholar]
  22. Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther. 1995;9 (Suppl 2):3–12. [PubMed] [Google Scholar]
  23. Telford J. L., Ghiara P. Prospects for the development of a vaccine against Helicobacter pylori. Drugs. 1996 Dec;52(6):799–804. doi: 10.2165/00003495-199652060-00002. [DOI] [PubMed] [Google Scholar]
  24. Valle J., Kekki M., Sipponen P., Ihamäki T., Siurala M. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol. 1996 Jun;31(6):546–550. doi: 10.3109/00365529609009126. [DOI] [PubMed] [Google Scholar]
  25. Williams J. R., Nokes D. J., Medley G. F., Anderson R. M. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect. 1996 Feb;116(1):71–89. doi: 10.1017/s0950268800058970. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES